Data_Sheet_1_Pretreatment diffusion-weighted imaging for prediction of relapsed and refractory primary central nervous system lymphoma.docx
收藏NIAID Data Ecosystem2026-05-01 收录
下载链接:
https://figshare.com/articles/dataset/Data_Sheet_1_Pretreatment_diffusion-weighted_imaging_for_prediction_of_relapsed_and_refractory_primary_central_nervous_system_lymphoma_docx/23917107
下载链接
链接失效反馈官方服务:
资源简介:
ObjectivesA subset of primary central nervous system lymphoma (PCNSL) has been shown to undergo an early relapsed/refractory (R/R) period after first-line chemotherapy. This study investigated the pretreatment clinical and MRI features to predict R/R in PCNSL, emphasizing the apparent diffusion coefficient (ADC) values in diffusion-weighted imaging (DWI).
MethodsThis retrospective study investigated the pretreatment MRI features for predicting R/R in PCNSL. Only patients who had undergone complete preoperative and postoperative MRI follow-up studies were included. From January 2006 to December 2021, 52 patients from two medical institutions with a diagnosis of PCNSL were included (median follow-up time, 26.3 months). Among these, 24 (46.2%) had developed R/R (median time to relapse, 13 months). Cox proportional hazard regression analyses were performed to determine hazard ratios for all parameters.
ResultsSignificant predictors of R/R in PCNSL were female sex, complete response (CR) to first-line chemotherapy, and ADC value/ratio (p < 0.05). Cut-off points of ADC values and ADC ratios for prediction of R/R were 0.68 × 10−3 mm2/s and 0.97, with AUCs of 0.78 and 0.77, respectively (p < 0.05). Multivariate Cox proportional hazards analysis showed that failure of CR to first-line chemotherapy and low ADC values (<0.68 × 10−3 mm2/s) were significant risk factors for R/R, with hazard ratios of 5.22 and 14.45, respectively (p < 0.05). Kaplan–Meier analysis showed that lower ADC values and ratios predicted significantly shorter progression-free survival (p < 0.05).
ConclusionPretreatment ADC values in DWI offer quantitative valuable information for the treatment planning in PCNSL.
创建时间:
2023-08-10



